Press Releases
& News

Barnik Invest Group is more than just an investment company.

Barnik Invest Group Announces the Formation of Barnik Holdings AB

Stockholm, Sweden – Barnik Invest Group, an investment firm dedicated to pioneering the advancement of innovative life science companies in the Nordics, today announced the formation of Barnik Holdings AB. This new holding company will serve as the umbrella entity for all Barnik Invest Group portfolio companies. Barnik Holdings AB will offer

Read More »

BoniPharmex Achieves Nationwide Distribution of FilVel® Products in Sweden

Stockholm, Sweden – BoniPharmex, a joint venture between StartUpPharma Int. AB, a wholly-owned subsidiary of Barnik Invest Group, and DynalisPharma, today announced the successful nationwide distribution of its FilVel® product line across all major pharmacies in Sweden, including Apotek Hjärtat, Apoteket AB, Kronans Apotek, Doz Apotek, Apotea, MEDS Apotek, and Apohem. BoniPharmex

Read More »

Barnik Invest Launches Cell4Cure AB to Advance Innovative Immunotherapy

Stockholm, Sweden – Barnik Invest Group is pleased to announce the official launch of Cell4Cure AB, a new company focused on developing advanced therapies based on antigen-specific dendritic cell mediated tolerance. This innovative approach aims to treat diseases where the immune system attacks the body’s own tissues. A consortium of former Idogen

Read More »

BoniPharmex Launches Five New Products in the Swedish Market

Stockholm, Sweden – BoniPharmex, a joint venture between StartUpPharma Int. AB, a wholly-owned subsidiary of Barnik Invest Group, and DynalisPharma, today announced the launch of five new products in the Swedish market. These innovative dietary supplements, collectively known as the FilVel® Solar System, offer a holistic approach to health and well-being. The

Read More »

Barnik Invest Acquires Idogen’s Technology Platform to Advance Immunotherapy

Stockholm, Sweden – Barnik Invest Group today announced the acquisition of Idogen AB’s technology platform. This strategic move positions Barnik Invest to lead the development of innovative therapies based on antigen-specific dendritic cell-mediated tolerance. The acquired technology platform holds immense potential to treat autoimmune diseases by modulating the immune system to target

Read More »

Barnik invest

Register with us today to access current investment opportunities